BPG is committed to discovery and dissemination of knowledge
Minireviews
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
Artif Intell Gastrointest Endosc. Sep 8, 2026; 7(2): 118493
Published online Sep 8, 2026. doi: 10.37126/aige.118493
Artificial intelligence for inflammatory bowel disease dysplasia detection: Current evidence and future directions
Ritesh Bhandari, Jack Gartlan, Philip Oppong, Puneet Chhabra
Ritesh Bhandari, Jack Gartlan, Puneet Chhabra, Department of Gastroenterology, Royal Hobart Hospital, Hobart 7000, Tasmania, Australia
Philip Oppong, Department of Gastroenterology, Southampton General Hospital, Southampton SO16 6YD, United Kingdom
Author contributions: Bhandari R, Chhabra P, Oppong P, and Gartlan J designed the research study; Bhandari R performed the literature search and wrote the initial manuscript draft; Chhabra P contributed the conceptual framework and clinical insights; Oppong P provided expert review and substantive content revisions; Gartlan J performed language editing, manuscript formatting, and reference verification; Bhandari R and Chhabra P revised the manuscript based on reviewer feedback; all authors critically reviewed and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Puneet Chhabra, DM, MD, FASGE, FRACP, MRCP, Department of Gastroenterology, Royal Hobart Hospital, No. 48 Liverpool Street, Hobart 7000, Tasmania, Australia. puneet.pgi@gmail.com
Received: January 4, 2026
Revised: January 28, 2026
Accepted: March 6, 2026
Published online: September 8, 2026
Processing time: 243 Days and 17.9 Hours
Core Tip

Core Tip: Dataset shift impairs non-inflammatory bowel disease (IBD) trained artificial intelligence’s (AI) ability in IBD dysplasia detection as they falter in inflamed colons and therefore IBD-specific models need to be developed. However, even with the IBD-trained models, various biases (selection, annotation, device) are seen which are amplified by training-deployment mismatches and affects generalizability as evident in external validation. This review compares performances, dissects these failures, and suggests a roadmap: Multicenter datasets, consensus labelling, federated learning, and multimodal models, bolstered by regulatory oversight and clinical workflows. Such integrated steps will help to generate equitable, reliable AI to enhance surveillance and avert colorectal cancer in IBD.

Write to the Help Desk